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Abstract As the human genome sequencing projects near
completion, there is an active search for technologies that can
provide insights into the genetic basis for physiological variation
and interpreting gene expression in terms of phenotype at the
whole organism level in order to understand the pathophysiology
of disease. We present a novel metabonomic approach to the
investigation of genetic influences on metabolic balance and
metabolite excretion patterns in two phenotypically normal
mouse models (C57BL10J and Alpk:ApfCD). Chemometric
techniques were applied to optimise recovery of biochemical
information from complex 1H NMR urine spectra and to
determine metabolic biomarker differences between the two
strains. Differences were observed in tricarboxylic acid cycle
intermediates and methylamine pathway activity. We suggest
here a new ‘metabotype’ concept, which will be of value in
relating quantitative physiological and biochemical data to both
phenotypic and genetic variation in animals and man. ß 2000
Federation of European Biochemical Societies. Published by
Elsevier Science B.V. All rights reserved.
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1. Introduction
In order to reap the bene¢ts of the human genome project
and other major programmes of genetic research, it is neces-
sary to correctly place genetic information in the context of
physiological and biochemical mechanisms in the whole or-
ganism. It is also imperative to understand the functional
consequences of genetic modi¢cation in transgenic organisms,
both from the point of view of witting and unwitting inter-
ventions.
Transcriptomic approaches utilising proprietary gene chips
can rapidly generate gene expression data, but genetic up/
down regulation needs to be related to physiological processes
that occur at various later time points. At one level, proteo-
mics can be used to study protein variation in relation to gene
expression [1]. However, proteomic methods are time consum-
ing and expensive, and still do not lead to a direct under-
standing of physiological consequences of genetic modi¢ca-
tion because: (a) proteins may have many post translational
modi¢cations that complicate understanding the relationships
to physiological function and (b) that proteins act ‘in concert’
to control physiological processes and are spatially and tem-
porally distributed in such a way that, with current scienti¢c
knowledge, proteomics is not readily predictive of biological
end-points, e.g. drug toxicity.
In consequence, we have developed an e⁄cient nuclear
magnetic resonance (NMR)-based metabonomic approach to
understanding pathophysiological and toxicological processes
[2^9], in which multivariate metabolic events over a period of
time can be interrogated using pattern recognition (PR) anal-
ysis methods. In principle metabonomics can be extended to
the study of genetic variation in experimental animals and
man. Thus we have previously de¢ned metabonomics as ‘the
quantitative measurement of the dynamic multiparametric
metabolic response of living systems to pathophysiological
stimuli or genetic modi¢cation’ [2].
High resolution 1H NMR spectroscopy presents an e⁄cient
and non-destructive means of simultaneously generating data
on hundreds (potentially thousands) of metabolites in bio-
£uids or tissues [10]. The metabolic status of the organism is
re£ected in the spectral pro¢le of a bio£uid and there are
species di¡erences observable in the basal NMR spectrum of
a bio£uid such as blood plasma [11]. The complexity of these
information-rich NMR spectral pro¢les provides a signi¢cant
analytical challenge, as does the relationship between the pro-
¢le and biological interpretation. However, information re-
covery can be maximised by applying multivariate statistical
tools to the analysis of these NMR data. We have shown that
1H NMR spectroscopy of biological matrices, coupled with
appropriate pattern recognition (PR) and multivariate statis-
tical analysis methods o¡ers a novel in vivo approach to the
investigation of drug toxicity. Applications of this metabo-
nomic technology include the identi¢cation of biomarkers of
toxicity and disease [4^6,12,13], monitoring sequential meta-
bolic perturbations in bio£uids and tissues following toxic
insult [7,8] and metabolic characterisation of physiological
variance in humans under mild physiological stress [14].
Various physiological factors a¡ect the metabolic composi-
tion of biological matrices including diet, state of health, di-
urnal cycles, genetic drift, stress and strain di¡erences and it is
necessary to characterise these di¡erences in order to distin-
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guish between physiological and pathophysiological responses
in animal models. Previous work has shown that it is possible
to distinguish between two strains of standard laboratory rat
(Han Wistar and Sprague Dawley) using NMR-based me-
tabonomic methods [9].
Mouse models are becoming increasingly important in risk
assessment and as models of human disease, particularly with
respect to the development of transgenic technology [15,16].
In this study we have applied 1H NMR-based metabonomic
techniques to characterise the urinary pro¢les of two exper-
imental mouse models viz. C57BL10J and Alpk:ApfCD,
which are both phenotypically normal, and to explore the
extent of physiological variation and metabolic di¡erences
between the two strains. This work shows the future potential
for the use of metabonomic studies in the investigation of
transgenic animals and other animal models of human disease
and the e¡ects of genetic manipulation on whole organ phys-
iology.
2. Materials and methods
2.1. Animal handling and collection of urine for 1H NMR spectroscopy
Urine samples were obtained from 6 week old C57BL10J mice
(n = 24) and Alpk:ApfCD mice (n = 28) by manipulation of the lower
abdomen. Samples were collected into glass vials and were stored at
320‡C pending NMR spectroscopic analysis. Prior to the study, ani-
mals were housed collectively in polycarbonate solid bottom cages,
according to strain, and were allowed free access to water and food.
Mice were fed pelleted irradiated rat and mouse diet 1 (Special Diet
Services, Witham, Essex, UK), from weaning until the end of the
experiment. Animals were maintained at room temperature with arti-
¢cial 12 h dark/12 h light cycles
2.2. Sample preparation and 1H NMR spectroscopy of whole mouse
urine
In order to control the sample pH to a narrow range, 300 mM
sodium phosphate bu¡er (pH 7.4) was added to the urine samples.
Due to the small volume of mouse urine available (typically 100 Wl),
sodium phosphate bu¡er was added to make the overall sample up to
200 Wl volume. This di¡erential dilution of the samples does not a¡ect
the PR analysis because of the normalisation processes used (see be-
low). 1H NMR spectra were acquired on a Bruker DRX-500 spec-
trometer at ambient temperature using the following standard pulse
sequence:
RD-90-t1-90-tm-90-acquire FID
Secondary irradiation of the water signal was achieved during the
mixing time tm (100 ms). Typically 256 free induction decays (FIDs)
were collected into 32k data points using a spectral width of 5995.204
Hz, utilising a 8.7 ms pulse width (90‡ pulse angle), an acquisition
time of 2.733 s, a relaxation delay of 2.3 s and a total pulse recycle
time of 5.033 s. The FIDs were multiplied by an exponential weighting
function corresponding to a line broadening of 0.3 Hz prior to FT.
The acquired NMR spectra were phased, baseline-corrected and ref-
erenced to hippurate (o-CH; N7.84).
2.3. Data reduction of the NMR spectra
The 1H NMR spectra (N0.2^9.7) were automatically data-reduced
to 193 integral segments using the AMIX (Analysis of MIXtures
software package, version 2.5, Bruker Analytische Messtechnik,
Karlsruhe, Germany) with the regions N6.0^4.52 set to zero integral.
The region N6.0^4.52 was excluded from the analysis in order to re-
move the e¡ects of variation in the suppression of the water resonance
and the e¡ects of variation in the urea signal caused by partial cross
solvent saturation via solvent exchanging protons. Each segment con-
sisted of the integral of the NMR region to which it was associated.
The data were normalised in Excel (Microsoft0, Excel 97, SR-2) and
then exported into the SIMCA-P (version 8.0, Umetrics, Umea, Swe-
den) software package. All subsequent analysis used centred scaling.
2.4. Principal components analysis (PCA) of the 1H NMR spectral
data
PCA is a data visualisation method that is useful for overviewing
relationships or ‘groupings’ within multivariate data [17]. The data are
represented in K-dimensional space (where K is equal to the number
of variables) and are subsequently reduced into a few principal com-
ponents which are descriptive dimensions that describe the maximum
variation within the data. Any prior knowledge relating to class mem-
bership is not used in the PCA analysis. The PCs can be displayed
graphically to yield a ‘scores plot’, which displays any patterns or
groupings within the data and can also be useful in highlighting out-
liers. A PCA model was constructed using all samples. The scores plot
of PC1 versus PC2 was examined for separation between the two
strains of mice: C57BL10J and Alpk:ApfCD (referred to as classes).
Where clusters are not distinctly separated in the scores plots and
groups overlap, it is desirable to ¢ne-tune the models to allow com-
plete distinction between groups. Furthermore, it can often arise that
the maximum variation, as represented by the PCs in PCA, may not
always produce the maximum separation between the classes. In these
cases it is possible to use methods which use other directions in multi-
variate space for establishing separations between classes. One such
method is partial least squares-discriminant analysis (PLS-DA).
2.5. Prediction of classes by PLS-DA
Having established the presence of strain-related clusters, data were
analysed by PLS-DA with a view to optimising the separation be-
tween the C57BL10J and Alpk:ApfCD strains.
PLS-DA is a linear regression method whereby the multivariate
variables corresponding to the observations (spectral descriptors) are
related to the class membership for each sample [18]. The method is
supervised, i.e. the class membership of the samples is included in the
calculation. PLS-DA provides an easily understood graphical means
to identifying the spectral regions of di¡erence between the classes and
also allows statistical evaluation as to whether the di¡erences between
classes are signi¢cant.
A PLS-DA model was calculated including all samples
(C57BL10J = class 1 and Alpk:ApfCD = class 2). For the purpose of
cross-validation, the samples were divided into a training set and a
validation set, each of equal size and comprising of V50% C57BL10J
and 50% Alpk:ApfCD, and a PLS-DA model was calculated for both
sets. The PLS-DA coe⁄cients were examined and compared for all
three PLS-DA models (whole set, training set and validation set) to
establish the spectral regions of variance between the C57BL10J and
Alpk:ApfCD strains.
To establish whether the di¡erences were signi¢cant between
strains, the PLS-DA model for training set was used to predict the
strain of samples in the validation set and vice versa. Class (strain)
membership was predicted using a value of 0.5 dividing line between
the two classes including values predicted using a class membership
probability value s 0.01.
Table 1
Summary of prediction results investigating two strains of mice by PLS-DA
PLS-DA model Percentage of correct predicted
classi¢cations for
Percentage of predictions with signi¢cance
6 0.01 for
one component model two component model one component model two component model
Alpk:ApfCD vs. C57BL10J (training set) 87 100 81 94
Alpk:ApfCD vs. C57BL10J (validation set) 87 98 85 94
Calculated using class membership probability s 0.01.
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3. Results
3.1. 1H NMR spectroscopy of urine samples from C57BL10J
and Alpk:ApfCD mice
Visual inspection of the 1H NMR urine spectra revealed
changes in the patterns associated with a variety of di¡erences
in the two strains (Fig. 1). Inter-animal variation in urine
composition and the complexity of the spectra, coupled with
di¡erences in the volume of urine excreted, makes visual com-
parison of spectra di⁄cult, hence chemometric methods of
spectral analysis were employed.
3.2. PCA of 1H NMR urinary data
The scores plot of PC1 versus PC2 showed that, with the
exception of one sample obtained from a Alpk:ApfCD
mouse, the samples were separated into two distinct clusters
relating to the strain in the ¢rst PC (Fig. 2). Samples obtained
from C57BL10J mice formed a tighter cluster than did those
from Alpk:ApfCD mice.
3.3. Investigation of the di¡erences between strains of
Alpk:ApfCD mice and C57BL10 by PLS-DA
PLS-DA was applied to these data to investigate whether
Alpk:ApfCD and C57BL10 mice were signi¢cantly di¡erent
in terms of their urinary metabolite pro¢le, and to determine
which metabolites showed the greatest variation between the
two strains. The prediction results are summarised in Table 1
and show that for a two component model, the strain of
mouse can be predicted accurately in 98% of cases. Further-
more, strain can be predicted with a signi¢cance level of
v 81% for a one component model and with a signi¢cance
level of v 94% for a two component model using a 99% con-
¢dence limit.
The regression coe⁄cients were plotted for the PLS-DA
models to investigate and indicate the major spectral varia-
tions between two strains (Fig. 3). The metabolites contained
within the selected regions (as determined from regression
coe⁄cient plots) were identi¢ed and have been summarised
in Table 2. The most signi¢cant metabolites distinguishing
between strains included 2-oxoglutarate, citrate, trimethyl-
amine-N-oxide, and guanidinoacetic acid (relatively higher
concentration in Alpk:ApfCD mice) together with taurine
and creatinine (relatively higher concentration in C57BL10
mice). Minor strain di¡erences in the urinary excretion of
hippurate and creatine were observed. In addition, the urinary
levels of both dimethylamine and trimethylamine were found
to be greater in C57BL10J mice, in contrast to trimethyl-
amine-N-oxide which was present in relatively higher concen-
trations in Alpk:ApfCD mice. Resonances from the methyl
groups of unassigned organic acids made a minor contribu-
tion to the discrimination between the two strains (Fig. 1,
Table 2).
Fig. 1. 500 MHz 1H NMR spectra of typical urine samples obtained from (a) Alpk:ApfCD mouse and (b) C57BL10J mouse. The ¢rst two
principal components of all the data described 65.5 and 52.9%, respectively, of the overall variance.
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4. Discussion
4.1. Strain variation in the biochemical composition of urine
In this study C57BL10J mice were found to excrete propor-
tionally higher concentrations of dimethylamine and tri-
methylamine, together with lower concentrations of trimethyl-
amine-N-oxide in their urine (Figs. 1 and 3). The methyl-
amines are present in the urine, plasma and gastric £uid of
rats. One of the principle roles of the methylamines is to act as
non-perturbing renal osmolytes. They are present in high con-
centrations in the kidney and serve to protect against high
concentrations and balance osmotic pressure between extra-
and intra-cellular £uid [19]. The major route of biosynthesis of
the methylamines derives from the degradation of dietary cho-
line which is metabolised to trimethylamine by the enzymes of
the gut micro£ora (Fig. 4) [20,21]. Betaine is also a degrada-
tion product of dietary choline, and in cases where the intes-
tinal micro£ora has been reduced, the urinary excretion of
betaine is elevated at the expense of dimethylamine and tri-
methylamine-N-oxide [22]. However, choline is not the sole
precursor of dimethylamine and synthesis can also occur via
endogenous pathways [23] and direct conversion to trimethyl-
amine-N-oxide can also occur [24]. Since both the C57BL10J
and Alpk:ApfCD mice used in this study were obtained from
colonies which have been maintained in the same laboratory
since 1967, it is likely that the di¡erence in dimethylamine:
trimethylamine-N-oxide and trimethylamine:trimethylamine-
N-oxide ratio in these murine models is due to strain di¡er-
ences in enzyme activity rather than the presence of di¡erent
gut micro£ora.
Urine samples from Alpk:ApfCD mice contained relatively
higher urinary levels of creatine and lower urinary concentra-
tions of guanidinoacetic acid in comparison with urine sam-
ples from C57BL10J mice. One route of biosynthesis for cre-
atine involves the transfer of a methyl group from S-
adenosylmethionine to guanidinoacetic acid, catalysed by the
Fig. 2. PC scores plot derived from the 1H NMR spectra of urine
samples obtained from Alpk:ApfCD and C57BL10J mice.
Table 2
Summary of di¡erences between Alpk:ApfCD and C57BL10 strains analysed by PLS-DA
Integrated spectral
region
Ratio of metabolite concentration
Alpk:ApfCD to C57BL10
N1H Metabolite(s) present in selected region
7.84 + 7.84, d hippurate
7.64 + 7.65, t
7.56 + 7.56, t
4.04 3 3 4.06, s creatinine
4.00^3.96 ++ 3.97, d hippurate
3.94, s creatine
3.92^3.8 ++ 3.80, s guanidinoacetic acid
3.44 33 3.43, t taurine
3.32 3 3.28, t taurine
3.28 ++ 3.28, t and
3.27, s
taurine* and TMAO
3.04 + 3.04, s and
3.05, s
creatine and creatinine**
3.00 ++ 3.02 2-oxoglutarate
2.92 + dimethylglycine
2.88 3 3 2.88 trimethylamine
2.48^2.72 +++ 2.80, d and
2.67, d
citrate
*** (decrease) 2.73, s dimethylamine
2.44 ++ 2.45, t 2-oxoglutarate
2.36^1.88 3 overlapping resonances including amino acids and N-acetyl
glycoproteins
1.78 3 1.76, m spermine
1.92 3 1.93 acetate
Abbreviations: trimethylamine-N-oxide (TMAO). Scale: a net increase/decrease in the integrated spectral regions for Alpk:ApfCD mice is indi-
cated by +/3= s 0.005 and 6 0.01, ++/3 3= s 0.05 and 6 0.1, +++/3 3 3= s 0.1 as determined by the regression coe⁄cients.
*TMAO decreased in white overlapped with taurine therefore only 3.32 buckets indicates that taurine is decreased, **resonances overlapped.
E¡ects are counter-acted, ***dimethylamine is present in decreased concentrations in Alpk:ApfCD mice. However, because the resonance for
dimethylamine is overlapped with citrate, the net change from the PLS statistics indicates a net increase for this spectral region in Alpk:ApfCD
mice.
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enzyme guanidinoacetate methyltransferase (GAMT) [25].
Therefore it is likely that the enzyme GAMT is slightly up-
regulated in the Alpk:ApfCD mouse.
Other signi¢cant strain di¡erences included the presence of
relatively lower urinary concentrations of citrate and succinate
in the C57BL10J mouse. These metabolites are intermediates
in the tricarboxylic acid cycle and may therefore indicate a
strain di¡erence in mitochondrial function or activity.
4.2. Validity of the NMR-based metabonomic approach
We have shown that 1H NMR-based metabonomic ap-
proaches are an e⁄cient means of generating metabolic bio-
£uid pro¢les for animal models, and indeed are sensitive
enough to distinguish between two closely related strains,
the Alpk:ApfCD mouse and the C57BL10 mouse. In this
study we were able to predict the correct strain of mouse
for 87% of the samples analysed with v81% of these samples
being signi¢cantly di¡erent from the other strain at the 99%
con¢dence limit (Table 1). Previous work using this technol-
ogy to di¡erentiate between the urinary pro¢les of two com-
monly used experimental rat strains (Han Wistar and Sprague
Dawley) also supports the contention that genetic strain var-
iation between animals markedly a¡ects their biochemical
pro¢les in physiologically normal animals [9]. This leads us
to suggest the novel concept of the ‘metabotype’ which we
de¢ne as ‘a probabalistic multiparametric description of an
organism in a given physiological state based on analysis of
its cell types, bio£uids or tissues’. The metabotype concept
could be widely applicable to de¢ne the metabolic consequen-
ces of a genetic modi¢cation or disease process that may not
Fig. 3. Regression coe⁄cients of the 1H NMR variables for Alpk:ApfCD mouse strain derived from the PLS-DA model of Alpk:ApfCD and
C57BL10J mouse strains. Each bar represents a spectral region covering 0.04 ppm. This plot shows how the 1H NMR metabolite pro¢le of the
Alpk:ApfCD strain di¡ers to that for the C57BL10J strain where a positive value indicates that relatively greater urinary concentrations of a
metabolite are present in the Alpk:ApfCD mouse.
Fig. 4. Schematic representation of the biosynthesis of the methyl-
amines.
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be directly observable from gross examination of the pheno-
type and has the advantage of being quantitative in n dimen-
sions, thus allowing statistical comparisons of genetic modi¢-
cation on physiological status.
The metabolic pro¢ling of murine bio£uids also o¡ers par-
ticular potential in the ¢eld of evaluating transgenic models of
disease and drug e⁄cacy. The correlation between genomic
and proteomic data has not, as yet, been de¢ned and little
is known regarding the e¡ect of gene expression on the holis-
tic function of the organism at a metabolic level. Metabonom-
ics thus o¡er the possibility of establishing a link between
gene expression and altered physiological function.
A further bene¢t of NMR-based metabonomics of bio£uids
is the capability of obtaining a sequential uninterrupted set of
bio£uid samples collected non-invasively over time [8], there-
by allowing continuous analysis of the metabolic pro¢le, un-
like genomic and proteomic analysis which can only provide a
‘snapshot’ picture of the status of a particular cell type. Since
the development of disease or toxicity is generally a dynamic
process, often with several phases each represented by a suite
of unique biochemical markers, the ability to monitor dynam-
ic metabolic pro¢les is useful.
We have shown in this study that the metabolite excretion
pro¢les in the Alpk:ApfCD mouse and the C57BL10 mouse,
which demonstrate no phenotypic abnormalities, are signi¢-
cantly di¡erent. Many of the metabolites that exhibit di¡er-
ences between strains are constituents of the same metabolic
pathways. Thus, we have shown that in principle NMR-based
metabonomics can be an e¡ective means of relating genetic
pro¢le of an organism to physiological function.
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